TRICIA RICKETTSFACEY: Open Payments
NPI 1619308475 · DANBURY, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$604 in 26 payments from 13 companies in 2025. Trend: 2023 $271 · 2024 $445 · 2025 $604
Food & beverage: $604
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 3 | $134 |
| Otsuka America Pharmaceutical, Inc. | 5 | $104 |
| AstraZeneca Pharmaceuticals LP | 4 | $78 |
| Exact Sciences Corporation | 2 | $44 |
| Lilly USA, LLC | 2 | $41 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $40 |
| Kowa Pharmaceuticals America, Inc. | 2 | $39 |
| Janssen Pharmaceuticals, Inc | 1 | $28 |
| Xeris Pharmaceuticals, Inc. | 1 | $25 |
| Intra-Sana Laboratories | 1 | $20 |
Products named: QULIPTA, REXULTI, BREZTRI, MOUNJARO, CAPLYTA, ZORYVE, SPRAVATO, GVOKE HYPOPEN.
Industry payments across CT — which companies pay providers there.
